Previous close | 0.0400 |
Open | 0.0420 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 0.0397 - 0.0420 |
52-week range | 0.0350 - 0.0770 |
Volume | |
Avg. volume | 96,648 |
Market cap | 15.759M |
Beta (5Y monthly) | 1.66 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0100 |
Earnings date | 29 Feb 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
PharmAla will consult on GMP Drug Product and Regulatory Development for Red Light HollandVANCOUVER, British Columbia, Feb. 09, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased that it has entered into a consulting relationship with Red Light Holland Corp. (“Red Light”), (CSE: TRIP) to consult
TORONTO, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Huxley Health Inc. (“Huxley” or the “Company”) is pleased to provide you with a comprehensive corporate update, highlighting significant milestones and developments that have shaped Huxley over the past year. Key Highlights: Acquisition of Sintalica Corp: Huxley strengthens its position in psychedelics-based treatments for Neuroinflammatory Disorders through the successful acquisition of Sintalica Corp.New Leadership: High profile additions creating a d